| 1 | Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis | 3.9 | 8 | Citations (PDF) |
| 2 | Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis | 1.0 | 7 | Citations (PDF) |
| 3 | Multiple sclerosis and COVID-19: interactions and unresolved issues | 17.9 | 3 | Citations (PDF) |
| 4 | Response to letter to the editor: ‘Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis’ | 3.9 | 0 | Citations (PDF) |
| 5 | Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis | 1.0 | 8 | Citations (PDF) |
| 6 | Managing patients with late-onset neutropenia during treatment with ocrelizumab | 3.9 | 0 | Citations (PDF) |
| 7 | Longitudinal motor system changes from acute to chronic spinal cord injury | 3.5 | 11 | Citations (PDF) |
| 8 | Temporal dynamics of white and gray matter plasticity during motor skill acquisition: a comparative diffusion tensor imaging and multiparametric mapping analysis | 2.8 | 5 | Citations (PDF) |
| 9 | The refined Pathways to Cures Research Roadmap for multiple sclerosis cures | 3.9 | 9 | Citations (PDF) |
| 10 | Evaluating multiple sclerosis severity loci 30 years after a clinically isolated syndrome | 3.6 | 4 | Citations (PDF) |
| 11 | Dynamics of progressive degeneration of major spinal pathways following spinal cord injury: A longitudinal study | 3.3 | 19 | Citations (PDF) |
| 12 | Navigating Through the Recent Diagnostic Criteria for MOGAD | 1.0 | 8 | Citations (PDF) |
| 13 | Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community | 3.9 | 7 | Citations (PDF) |
| 14 | Multiple sclerosis: time for early treatment with high-efficacy drugs | 3.4 | 76 | Citations (PDF) |
| 15 | Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique | 3.3 | 9 | Citations (PDF) |
| 16 | Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal | 3.9 | 13 | Citations (PDF) |
| 17 | Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients | 3.3 | 8 | Citations (PDF) |
| 18 | Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction? | 3.9 | 12 | Citations (PDF) |
| 19 | Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis | 3.9 | 12 | Citations (PDF) |
| 20 | Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data | 13.7 | 222 | Citations (PDF) |
| 21 | Cortical involvement determines impairment 30 years after a clinically isolated syndromeBrain, 2021, 144, 1384-1395 | 8.4 | 52 | Citations (PDF) |
| 22 | Longitudinal changes of spinal cord grey and white matter following spinal cord injury | 6.3 | 42 | Citations (PDF) |
| 23 | Clinical relevance of cortical network dynamics in early primary progressive MS | 3.9 | 16 | Citations (PDF) |
| 24 | Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort | 3.9 | 47 | Citations (PDF) |
| 25 | Reduced neurite density in the brain and cervical spinal cord in relapsing–remitting multiple sclerosis: A NODDI study | 3.9 | 59 | Citations (PDF) |
| 26 | A 30‐Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes | 6.6 | 94 | Citations (PDF) |
| 27 | Pathologic correlates of the magnetization transfer ratio in multiple sclerosis | 1.0 | 47 | Citations (PDF) |
| 28 | The 2013 clinical course descriptors for multiple sclerosis | 1.0 | 116 | Citations (PDF) |
| 29 | Aggressive multiple sclerosis (2): Treatment | 3.9 | 38 | Citations (PDF) |
| 30 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype | 3.9 | 73 | Citations (PDF) |
| 31 | Disrupted principal network organisation in multiple sclerosis relates to disability | 3.4 | 3 | Citations (PDF) |
| 32 | MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers | 17.9 | 203 | Citations (PDF) |
| 33 | Traumatic and nontraumatic spinal cord injury: pathological insights from neuroimaging | 28.6 | 202 | Citations (PDF) |
| 34 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders | 17.9 | 159 | Citations (PDF) |
| 35 | Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis | 7.5 | 38 | Citations (PDF) |
| 36 | Structural network disruption markers explain disability in multiple sclerosis | 6.3 | 45 | Citations (PDF) |
| 37 | Progressive neurodegeneration following spinal cord injury | 1.0 | 127 | Citations (PDF) |
| 38 | Dorsal and ventral horn atrophy is associated with clinical outcome after spinal cord injury | 1.0 | 58 | Citations (PDF) |
| 39 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis | 3.9 | 618 | Citations (PDF) |
| 40 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria | 17.9 | 7,452 | Citations (PDF) |
| 41 | Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting | 28.6 | 148 | Citations (PDF) |
| 42 | Deep gray matter volume loss drives disability worsening in multiple sclerosis | 6.6 | 423 | Citations (PDF) |
| 43 | Multiple sclerosis | 62.1 | 1,736 | Citations (PDF) |
| 44 | Landscape of MS patient cohorts and registries: Recommendations for maximizing impact | 3.9 | 35 | Citations (PDF) |
| 45 | Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis | 3.9 | 44 | Citations (PDF) |
| 46 | Quantitative MRI of rostral spinal cord and brain regions is predictive of functional recovery in acute spinal cord injury | 3.3 | 66 | Citations (PDF) |
| 47 | Progression of regional grey matter atrophy in multiple sclerosisBrain, 2018, 141, 1665-1677 | 8.4 | 372 | Citations (PDF) |
| 48 | New insights into the burden and costs of multiple sclerosis in Europe | 3.9 | 672 | Citations (PDF) |
| 49 | Challenge of progressive multiple sclerosis therapy | 3.8 | 22 | Citations (PDF) |
| 50 | Exercise in patients with multiple sclerosis | 17.9 | 427 | Citations (PDF) |
| 51 | New diagnostic criteria and phenotypes of MS | 2.1 | 2 | Citations (PDF) |
| 52 | New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom | 3.9 | 35 | Citations (PDF) |
| 53 | Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function | 62.1 | 282 | Citations (PDF) |
| 54 | Cell-based therapeutic strategies for multiple sclerosisBrain, 2017, 140, 2776-2796 | 8.4 | 170 | Citations (PDF) |
| 55 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper | 3.9 | 144 | Citations (PDF) |
| 56 | Voxel-based analysis of grey and white matter degeneration in cervical spondylotic myelopathy | 3.4 | 63 | Citations (PDF) |
| 57 | Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest | 1.0 | 77 | Citations (PDF) |
| 58 | Embodied neurology: an integrative framework for neurological disordersBrain, 2016, 139, 1855-1861 | 8.4 | 43 | Citations (PDF) |
| 59 | White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis | 3.9 | 31 | Citations (PDF) |
| 60 | White and gray matter damage in primary progressive MS | 1.0 | 41 | Citations (PDF) |
| 61 | The challenge of comorbidity in clinical trials for multiple sclerosis | 1.0 | 60 | Citations (PDF) |
| 62 | Recommendations for observational studies of comorbidity in multiple sclerosis | 1.0 | 81 | Citations (PDF) |
| 63 | Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritisBrain, 2016, 139, 816-828 | 8.4 | 85 | Citations (PDF) |
| 64 | DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime? | 6.3 | 44 | Citations (PDF) |
| 65 | Tracking sensory system atrophy and outcome prediction in spinal cord injury | 6.6 | 94 | Citations (PDF) |
| 66 | A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses | 2.3 | 7 | Citations (PDF) |
| 67 | Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosisBrain, 2015, 138, 1568-1582 | 8.4 | 58 | Citations (PDF) |
| 68 | Predicting outcome in clinically isolated syndrome using machine learning | 3.3 | 74 | Citations (PDF) |
| 69 | Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosisBrain, 2015, 138, 2584-2595 | 8.4 | 115 | Citations (PDF) |
| 70 | Progressive MS: from pathophysiology to drug discovery | 3.9 | 36 | Citations (PDF) |
| 71 | Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions | 6.3 | 89 | Citations (PDF) |
| 72 | Spatial variability and changes of metabolite concentrations in the cortico‐spinal tract in multiple sclerosis using coronal CSI | 3.5 | 12 | Citations (PDF) |
| 73 | Pharmacological management of pain in Australian Aged Care Facilities | 1.8 | 30 | Citations (PDF) |
| 74 | Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis | 4.4 | 52 | Citations (PDF) |
| 75 | A novel approach with “skeletonised MTR” measures tract‐specific microstructural changes in early primary‐progressive MS | 3.5 | 13 | Citations (PDF) |
| 76 | Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB
1
cannabinoid receptor agonists | 0.6 | 32 | Citations (PDF) |
| 77 | Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis | 1.0 | 27 | Citations (PDF) |
| 78 | HLA-DRB1*15 influences the development of brain tissue damage in early PPMS | 1.0 | 23 | Citations (PDF) |
| 79 | Defining the clinical course of multiple sclerosis | 1.0 | 3,036 | Citations (PDF) |
| 80 | Age Related Changes in Metabolite Concentrations in the Normal Spinal Cord | 2.3 | 16 | Citations (PDF) |
| 81 | Early Neuronal Damage In The Cervical Cord Of Patients With Primary Progressive Multiple Sclerosis Demonstrated By MR Spectroscopy And q-space Imaging (S54.003) | 1.0 | 0 | Citations (PDF) |
| 82 | Corpus callosum damage predicts disability progression and cognitive dysfunction in primary‐progressive MS after five years | 3.5 | 52 | Citations (PDF) |
| 83 | MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study | 17.9 | 274 | Citations (PDF) |
| 84 | Low Myo‐inositol indicating astrocytic damage in a case series of neuromyelitis optica | 6.6 | 47 | Citations (PDF) |
| 85 | Metabolic Changes in the Spinal Cord After Brachial Plexus Root Re-implantation | 3.4 | 20 | Citations (PDF) |
| 86 | Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis | 3.9 | 37 | Citations (PDF) |
| 87 | Tracking Changes following Spinal Cord Injury | 4.3 | 93 | Citations (PDF) |
| 88 | Impact on Clinical and Cost Outcomes of a Centralized Approach to Acute Stroke Care in London: A Comparative Effectiveness Before and After Model | 2.3 | 90 | Citations (PDF) |
| 89 | Primary Progressive Multiple Sclerosis | 6.3 | 30 | Citations (PDF) |
| 90 | Multiple Sclerosis in the UK | 3.6 | 97 | Citations (PDF) |
| 91 | Axonal integrity predicts cortical reorganisation following cervical injury | 6.3 | 70 | Citations (PDF) |
| 92 | Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS | 3.9 | 119 | Citations (PDF) |
| 93 | Changes in Auditory Feedback Connections Determine the Severity of Speech Processing Deficits after Stroke | 3.7 | 36 | Citations (PDF) |
| 94 | Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis | 3.9 | 36 | Citations (PDF) |
| 95 | What sample sizes for reliability and validity studies in neurology? | 3.4 | 180 | Citations (PDF) |
| 96 | Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis | 1.3 | 52 | Citations (PDF) |
| 97 | Linking white matter tracts to associated cortical grey matter: A tract extension methodology | 4.4 | 17 | Citations (PDF) |
| 98 | Neuroplasticity and functional recovery in multiple sclerosis | 28.6 | 152 | Citations (PDF) |
| 99 | Degeneration of the Injured Cervical Cord Is Associated with Remote Changes in Corticospinal Tract Integrity and Upper Limb Impairment | 2.3 | 64 | Citations (PDF) |
| 100 | Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study | 17.9 | 594 | Citations (PDF) |
| 101 | The self‐report Barthel Index: preliminary validation in people with Parkinson’s disease | 3.5 | 35 | Citations (PDF) |
| 102 | Treatment of cognitive impairment in multiple sclerosis: position paper | 3.4 | 206 | Citations (PDF) |
| 103 | Early pericalcarine atrophy in acute optic neuritis is associated with conversion to multiple sclerosis | 6.3 | 23 | Citations (PDF) |
| 104 | MRI only conversion to multiple sclerosis following a clinically isolated syndrome | 6.3 | 44 | Citations (PDF) |
| 105 | A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis | 3.9 | 73 | Citations (PDF) |
| 106 | Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury | 3.5 | 83 | Citations (PDF) |
| 107 | The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments | 2.0 | 110 | Citations (PDF) |
| 108 | Asymmetric hemispheric representation of periictal heart rate modulation is individually lateralised | 1.8 | 11 | Citations (PDF) |
| 109 | A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS) | 2.9 | 4 | Citations (PDF) |
| 110 | Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria | 6.6 | 8,696 | Citations (PDF) |
| 111 | Disability, atrophy and cortical reorganization following spinal cord injuryBrain, 2011, 134, 1610-1622 | 8.4 | 277 | Citations (PDF) |
| 112 | Cervical cord and brain grey matter atrophy independently associate with long-term MS disability | 6.3 | 56 | Citations (PDF) |
| 113 | A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients | 6.3 | 10 | Citations (PDF) |
| 114 | Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS | 6.3 | 21 | Citations (PDF) |
| 115 | Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis | 3.9 | 34 | Citations (PDF) |
| 116 | Dissecting structure–function interactions in acute optic neuritis to investigate neuroplasticity | 3.5 | 37 | Citations (PDF) |
| 117 | Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions | 17.9 | 158 | Citations (PDF) |
| 118 | Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis | 2.3 | 9 | Citations (PDF) |
| 119 | Neuroplasticity predicts outcome of optic neuritis independent of tissue damage | 6.6 | 80 | Citations (PDF) |
| 120 | Reply | 6.6 | 0 | Citations (PDF) |
| 121 | Scanning Laser Polarimetry Quantification of Retinal Nerve Fiber Layer Thinning Following Optic Neuritis | 1.0 | 9 | Citations (PDF) |
| 122 | Effect sizes can be misleading: is it time to change the way we measure change? | 6.3 | 50 | Citations (PDF) |
| 123 | Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis | 1.0 | 61 | Citations (PDF) |
| 124 | Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes | 6.3 | 84 | Citations (PDF) |
| 125 | Spinal cord repair in MS | 1.0 | 58 | Citations (PDF) |
| 126 | Refinement and validation of the Parental Illness Impact Scale | 2.6 | 13 | Citations (PDF) |
| 127 | The search for responsive clinical endpoints in primary progressive multiple sclerosis | 3.9 | 32 | Citations (PDF) |
| 128 | The challenge of follow-on biologics for treatment of multiple sclerosis | 1.0 | 25 | Citations (PDF) |
| 129 | Early MRI in optic neuritis | 1.0 | 91 | Citations (PDF) |
| 130 | Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis | 3.9 | 42 | Citations (PDF) |
| 131 | MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction | 3.9 | 86 | Citations (PDF) |
| 132 | The size of the treatment effect: do patients and proxies agree? | 1.9 | 9 | Citations (PDF) |
| 133 | Investigation of white matter pathology in ALS and PLS using tract‐based spatial statistics | 3.5 | 127 | Citations (PDF) |
| 134 | Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study | 3.5 | 60 | Citations (PDF) |
| 135 | Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM | 3.5 | 174 | Citations (PDF) |
| 136 | Texture analysis of magnetization transfer maps from patients with clinically isolated syndrome and multiple sclerosis | 3.4 | 26 | Citations (PDF) |
| 137 | Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis | 3.4 | 98 | Citations (PDF) |
| 138 | Volumetric Examination of MS Plaques and Correlation with EDSS Ratings | 1.0 | 0 | Citations (PDF) |
| 139 | Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition | 1.3 | 52 | Citations (PDF) |
| 140 | Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging | 3.4 | 27 | Citations (PDF) |
| 141 | A three-year, multi-parametric MRI study in patients at presentation with CIS | 3.4 | 65 | Citations (PDF) |
| 142 | Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study | 6.6 | 106 | Citations (PDF) |
| 143 | Gray matter atrophy is related to long‐term disability in multiple sclerosis | 6.6 | 462 | Citations (PDF) |
| 144 | Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi‐centre fMRI study | 3.5 | 80 | Citations (PDF) |
| 145 | Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years | 1.9 | 8 | Citations (PDF) |
| 146 | MRI in multiple sclerosis: current status and future prospects | 17.9 | 315 | Citations (PDF) |
| 147 | Diffusion-based tractography in neurological disorders: concepts, applications, and future developments | 17.9 | 384 | Citations (PDF) |
| 148 | Multiple sclerosis—a global disorder and still poorly managed | 17.9 | 21 | Citations (PDF) |
| 149 | The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? | 2.9 | 25 | Citations (PDF) |
| 150 | Reproducibility of fMRI in the clinical setting: Implications for trial designs | 4.4 | 51 | Citations (PDF) |
| 151 | Responsiveness and predictive value of EDSS and MSFC in primary progressive MS | 1.0 | 54 | Citations (PDF) |
| 152 | Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosisBrain, 2008, 131, 808-817 | 8.4 | 840 | Citations (PDF) |
| 153 | Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease | 6.3 | 46 | Citations (PDF) |
| 154 | The patient's experience of being a human subject | 1.8 | 11 | Citations (PDF) |
| 155 | Magnetization Transfer Ratio in Gray Matter | 6.8 | 62 | Citations (PDF) |
| 156 | Neurorehabilitation in Multiple Sclerosis | 0.6 | 0 | Citations (PDF) |
| 157 | Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosisBrain, 2007, 130, 2220-2231 | 8.4 | 159 | Citations (PDF) |
| 158 | Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis | 3.9 | 44 | Citations (PDF) |
| 159 | Normal-appearing grey and white matter T1 abnormality in early relapsing–remitting multiple sclerosis: a longitudinal study | 3.9 | 46 | Citations (PDF) |
| 160 | Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis | 6.8 | 73 | Citations (PDF) |
| 161 | Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study | 3.9 | 11 | Citations (PDF) |
| 162 | Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability | 4.4 | 103 | Citations (PDF) |
| 163 | Two-dimensional population map of cortical connections in the human internal capsule | 3.4 | 62 | Citations (PDF) |
| 164 | The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke | 3.5 | 154 | Citations (PDF) |
| 165 | MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study | 17.9 | 299 | Citations (PDF) |
| 166 | Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations | 17.9 | 453 | Citations (PDF) |
| 167 | MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain | 3.4 | 91 | Citations (PDF) |
| 168 | Optic nerve diffusion tensor imaging in optic neuritis | 4.4 | 159 | Citations (PDF) |
| 169 | Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy | 4.4 | 186 | Citations (PDF) |
| 170 | Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis | 1.4 | 36 | Citations (PDF) |
| 171 | Functional anatomy of interhemispheric cortical connections in the human brain | 1.8 | 213 | Citations (PDF) |
| 172 | Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis | 3.4 | 62 | Citations (PDF) |
| 173 | Localization of grey matter atrophy in early RRMS | 3.4 | 106 | Citations (PDF) |
| 174 | Talking the talk on walking the walk | 3.4 | 59 | Citations (PDF) |
| 175 | Can we quantify the benefits of DMDs in multiple sclerosis? | 17.9 | 0 | Citations (PDF) |
| 176 | Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial | 17.9 | 41 | Citations (PDF) |
| 177 | Upper cervical cord area in early relapsing-remitting multiple sclerosis: Cross-sectional study of factors influencing cord size | 3.4 | 49 | Citations (PDF) |
| 178 | Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)Brain, 2006, 129, 224-234 | 8.4 | 165 | Citations (PDF) |
| 179 | Selective magnetization transfer ratio decrease in the visual cortex following optic neuritisBrain, 2006, 129, 1031-1039 | 8.4 | 90 | Citations (PDF) |
| 180 | Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosisBrain, 2006, 129, 1859-1871 | 8.4 | 183 | Citations (PDF) |
| 181 | CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia | 1.0 | 51 | Citations (PDF) |
| 182 | Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study | 6.3 | 64 | Citations (PDF) |
| 183 | Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study | 6.3 | 67 | Citations (PDF) |
| 184 | Longitudinal Changes in Cerebral Response to Proprioceptive Input in Individual Patients after Stroke: An fMRI Study | 3.4 | 67 | Citations (PDF) |
| 185 | Exploring disability rating scale responsiveness II: Do more response options help? | 1.0 | 30 | Citations (PDF) |
| 186 | Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes | 6.3 | 174 | Citations (PDF) |
| 187 | Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life | 6.3 | 20 | Citations (PDF) |
| 188 | Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis | 6.8 | 162 | Citations (PDF) |
| 189 | Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis | 6.3 | 63 | Citations (PDF) |
| 190 | De-stabilizing and training effects of foot orthoses in multiple sclerosis | 3.9 | 40 | Citations (PDF) |
| 191 | Motor system activation after subcortical stroke depends on corticospinal system integrityBrain, 2006, 129, 809-819 | 8.4 | 408 | Citations (PDF) |
| 192 | The Evolution of Prefrontal Inputs to the Cortico-pontine System: Diffusion Imaging Evidence from Macaque Monkeys and Humans | 2.8 | 276 | Citations (PDF) |
| 193 | Neurorehabilitation in multiple sclerosis: foundations, facts and fiction | 3.8 | 32 | Citations (PDF) |
| 194 | Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis | 17.9 | 545 | Citations (PDF) |
| 195 | Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management | 17.9 | 131 | Citations (PDF) |
| 196 | Optic radiation changes after optic neuritis detected by tractography-based group mapping | 3.5 | 115 | Citations (PDF) |
| 197 | Adaptive cortical plasticity in higher visual areas after acute optic neuritis | 6.6 | 105 | Citations (PDF) |
| 198 | Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis | 6.6 | 494 | Citations (PDF) |
| 199 | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | 6.6 | 4,715 | Citations (PDF) |
| 200 | Identifying brain regions for integrative sensorimotor processing with ankle movements | 1.3 | 145 | Citations (PDF) |
| 201 | The impact of inpatient neurorehabilitation on psychological well–being on discharge and at 3 month follow–up | 3.4 | 8 | Citations (PDF) |
| 202 | Factors influencing work retention for people with multiple sclerosis | 3.4 | 108 | Citations (PDF) |
| 203 | Increasing normal–appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing–remitting multiple sclerosis | 3.4 | 72 | Citations (PDF) |
| 204 | The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis | 3.4 | 23 | Citations (PDF) |
| 205 | Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up | 6.3 | 300 | Citations (PDF) |
| 206 | Functional–Anatomical Validation and Individual Variation of Diffusion Tractography-based Segmentation of the Human Thalamus | 2.8 | 544 | Citations (PDF) |
| 207 | How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales | 6.3 | 118 | Citations (PDF) |
| 208 | A longitudinal study of cognition in primary progressive multiple sclerosisBrain, 2005, 128, 2891-2898 | 8.4 | 104 | Citations (PDF) |
| 209 | Multiple sclerosis: diagnosis and the management of acute relapses | 1.6 | 82 | Citations (PDF) |
| 210 | Emergence of thalamic magnetization transfer ratio abnormality in early relapsing—remitting multiple sclerosis | 3.9 | 36 | Citations (PDF) |
| 211 | Is inflammation important in early PPMS? a longitudinal MRI study | 6.3 | 62 | Citations (PDF) |
| 212 | Interferon beta-1b treatment does not induce autoantibodies | 1.0 | 29 | Citations (PDF) |
| 213 | Evaluating neurorehabilitation: lessons from routine data collection | 6.3 | 29 | Citations (PDF) |
| 214 | Metabolite Changes in Normal-Appearing Gray and White Matter Are Linked With Disability in Early Primary Progressive Multiple Sclerosis | 6.8 | 114 | Citations (PDF) |
| 215 | Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal studyBrain, 2005, 128, 1454-1460 | 8.4 | 140 | Citations (PDF) |
| 216 | Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosisBrain, 2005, 128, 2911-2925 | 8.4 | 103 | Citations (PDF) |
| 217 | Gray and white matter volume changes in early RRMS | 1.0 | 161 | Citations (PDF) |
| 218 | Metabolite changes in early relapsing–remitting multiple sclerosis | 3.4 | 69 | Citations (PDF) |
| 219 | Serial magnetization transfer imaging in acute optic neuritisBrain, 2004, 127, 692-700 | 8.4 | 113 | Citations (PDF) |
| 220 | Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study | 3.9 | 25 | Citations (PDF) |
| 221 | Estimation of the macromolecular proton fraction and bound pool T2 in multiple sclerosis | 3.9 | 46 | Citations (PDF) |
| 222 | Capturing the true burden of dystonia on patients | 1.0 | 99 | Citations (PDF) |
| 223 | The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis | 6.3 | 9 | Citations (PDF) |
| 224 | Overview of London trial of intramuscular interferon- 1a in primary progressive multiple sclerosis | 3.9 | 4 | Citations (PDF) |
| 225 | Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis | 3.9 | 128 | Citations (PDF) |
| 226 | Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis | 6.3 | 68 | Citations (PDF) |
| 227 | Overview of London trial of intramuscular interferon-b1a in primary-progressive multiple sclerosis | 3.9 | 6 | Citations (PDF) |
| 228 | Self-efficacy predicts self-reported health status in multiple sclerosis | 3.9 | 107 | Citations (PDF) |
| 229 | Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromesBrain, 2004, 127, 1101-1107 | 8.4 | 340 | Citations (PDF) |
| 230 | Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction | 3.9 | 45 | Citations (PDF) |
| 231 | Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosisBrain, 2004, 127, 1361-1369 | 8.4 | 203 | Citations (PDF) |
| 232 | A serial MRI study following optic nerve mean area in acute optic neuritisBrain, 2004, 127, 2498-2505 | 8.4 | 130 | Citations (PDF) |
| 233 | Interferon beta-1b in secondary progressive MS | 1.0 | 230 | Citations (PDF) |
| 234 | Integrated care pathways: disease-specific or process-specific? | 1.3 | 7 | Citations (PDF) |
| 235 | Abnormalities of cerebral perfusion in multiple sclerosis | 6.3 | 122 | Citations (PDF) |
| 236 | Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes | 6.8 | 33 | Citations (PDF) |
| 237 | Visual recovery following acute optic neuritis | 3.4 | 100 | Citations (PDF) |
| 238 | Patient dissatisfaction: Insights into the rehabilitation process | 3.4 | 7 | Citations (PDF) |
| 239 | European validation of a standardized clinical description of multiple sclerosis | 3.4 | 42 | Citations (PDF) |
| 240 | Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a | 1.6 | 12 | Citations (PDF) |
| 241 | The influence of time after stroke on brain activations during a motor task | 6.6 | 129 | Citations (PDF) |
| 242 | Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis | 3.9 | 59 | Citations (PDF) |
| 243 | Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite | 3.9 | 66 | Citations (PDF) |
| 244 | Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke | 4.0 | 112 | Citations (PDF) |
| 245 | Characterizing function–structure relationships in the human visual system with functional MRI and diffusion tensor imaging | 4.4 | 155 | Citations (PDF) |
| 246 | Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis | 4.4 | 84 | Citations (PDF) |
| 247 | Unterschiede im Genexpressionsmuster bei schubförmiger und primär progredienter Multipler Sklerose | 0.2 | 0 | Citations (PDF) |
| 248 | Serum gelatinase B/MMP-9 in primary
progressive multiple sclerosis patients treated with
interferon-beta-1a | 3.4 | 15 | Citations (PDF) |
| 249 | Socio-demographic variables are limited predictors of health status in multiple sclerosis | 3.4 | 9 | Citations (PDF) |
| 250 | Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? | 3.4 | 54 | Citations (PDF) |
| 251 | Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis | 3.4 | 226 | Citations (PDF) |
| 252 | The normal appearing grey matter in primary progressive multiple sclerosis | 3.4 | 112 | Citations (PDF) |
| 253 | A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging | 3.4 | 168 | Citations (PDF) |
| 254 | Effects of a short outpatient
rehabilitation treatment on disability of multiple sclerosis
patients | 3.4 | 93 | Citations (PDF) |
| 255 | The therapeutic potential of cannabis | 17.9 | 313 | Citations (PDF) |
| 256 | Spinal-cord MRI in multiple sclerosis | 17.9 | 231 | Citations (PDF) |
| 257 | Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis | 3.4 | 68 | Citations (PDF) |
| 258 | New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes | 6.6 | 87 | Citations (PDF) |
| 259 | Interferon beta-1a in primary progressive multiple sclerosis | 2.1 | 28 | Citations (PDF) |
| 260 | From diffusion tractography to quantitative white matter tract measures: a reproducibility study | 4.4 | 225 | Citations (PDF) |
| 261 | Diffusion tractography based group mapping of major white-matter pathways in the human brain | 4.4 | 117 | Citations (PDF) |
| 262 | Diagnosis of MS: a comparison of three different clinical settings | 3.9 | 7 | Citations (PDF) |
| 263 | Cannabinoids inhibit neurodegeneration in models of multiple sclerosisBrain, 2003, 126, 2191-2202 | 8.4 | 346 | Citations (PDF) |
| 264 | Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b | 1.0 | 137 | Citations (PDF) |
| 265 | Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial | 62.1 | 777 | Citations (PDF) |
| 266 | Towards a European Network for Multiple Sclerosis Trials (ENMST) | 3.9 | 3 | Citations (PDF) |
| 267 | The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study | 6.3 | 84 | Citations (PDF) |
| 268 | Expression of 2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study | 6.3 | 23 | Citations (PDF) |
| 269 | Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin? | 3.9 | 37 | Citations (PDF) |
| 270 | Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles | 6.3 | 110 | Citations (PDF) |
| 271 | Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in amyotrophic lateral sclerosis | 6.3 | 167 | Citations (PDF) |
| 272 | Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities | 3.9 | 86 | Citations (PDF) |
| 273 | Measuring the impact of MS on walking ability | 1.0 | 811 | Citations (PDF) |
| 274 | C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings | 3.9 | 51 | Citations (PDF) |
| 275 | Neutralising antibodies to interferon during the treatment of multiple sclerosis | 6.3 | 15 | Citations (PDF) |
| 276 | Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b | 1.0 | 45 | Citations (PDF) |
| 277 | Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales | 3.9 | 76 | Citations (PDF) |
| 278 | Primary progressive multiple sclerosis: a 5-year clinical and MR studyBrain, 2003, 126, 2528-2536 | 8.4 | 119 | Citations (PDF) |
| 279 | Interferon β-1a in primary progressive MS | 1.0 | 254 | Citations (PDF) |
| 280 | Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples | 6.3 | 147 | Citations (PDF) |
| 281 | Two-year follow-up study of primary and transitional progressive multiple sclerosis | 3.9 | 43 | Citations (PDF) |
| 282 | Integrated care pathways: outcome from inpatient rehabilitation following nontraumatic spinal cord lesion | 3.1 | 9 | Citations (PDF) |
| 283 | Quality of Life Measurement After Stroke | 5.9 | 171 | Citations (PDF) |
| 284 | A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis | 34.5 | 823 | Citations (PDF) |
| 285 | T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis | 3.9 | 36 | Citations (PDF) |
| 286 | Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis | 3.9 | 62 | Citations (PDF) |
| 287 | Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? | 6.3 | 47 | Citations (PDF) |
| 288 | Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevanceBrain, 2002, 125, 1676-1695 | 8.4 | 559 | Citations (PDF) |
| 289 | Brain atrophy in clinically early relapsing–remitting multiple sclerosisBrain, 2002, 125, 327-337 | 8.4 | 431 | Citations (PDF) |
| 290 | Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis | 6.3 | 144 | Citations (PDF) |
| 291 | Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosisBrain, 2002, 125, 2342-2352 | 8.4 | 262 | Citations (PDF) |
| 292 | Progress in neurorehabilitation in multiple sclerosis | 3.8 | 14 | Citations (PDF) |
| 293 | Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation | 0.1 | 24 | Citations (PDF) |
| 294 | Functional magnetic resonance imaging of the cortical response to photic stimulation in humans following optic neuritis recovery | 1.9 | 61 | Citations (PDF) |
| 295 | Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis | 6.6 | 256 | Citations (PDF) |
| 296 | The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM‐based segmentation methodology | 3.4 | 138 | Citations (PDF) |
| 297 | Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR | 3.4 | 37 | Citations (PDF) |
| 298 | Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy | 3.4 | 31 | Citations (PDF) |
| 299 | The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis | 3.4 | 69 | Citations (PDF) |
| 300 | Magnetisation transfer ratio histogram analysis of primary progressive and other multiple sclerosis subgroups | 2.1 | 34 | Citations (PDF) |
| 301 | Asymmetrical Activation of Human Visual Cortex Demonstrated by Functional MRI with Monocular Stimulation | 4.4 | 37 | Citations (PDF) |
| 302 | Adjusting to disfigurement: processes involved in dealing with being visibly different | 9.2 | 375 | Citations (PDF) |
| 303 | The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measureBrain, 2001, 124, 962-973 | 8.4 | 1,015 | Citations (PDF) |
| 304 | Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis | 3.4 | 81 | Citations (PDF) |
| 305 | T1 hypointensity of the spinal cord in multiple sclerosis | 3.4 | 23 | Citations (PDF) |
| 306 | A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis | 3.4 | 75 | Citations (PDF) |
| 307 | Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study | 3.4 | 137 | Citations (PDF) |
| 308 | T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow‐up study | 3.5 | 88 | Citations (PDF) |
| 309 | Diffusion tensor imaging in early relapsing-remitting multiple sclerosis | 3.9 | 73 | Citations (PDF) |
| 310 | Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study | 3.9 | 72 | Citations (PDF) |
| 311 | Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations | 1.0 | 327 | Citations (PDF) |
| 312 | MRI and assessment of treatment in multiple sclerosisBrain, 2001, 124, 1052-1053 | 8.4 | 1 | Citations (PDF) |
| 313 | Interferon-β1b in the treatment of secondary progressive MS | 1.0 | 71 | Citations (PDF) |
| 314 | Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS | 1.0 | 139 | Citations (PDF) |
| 315 | The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results | 3.9 | 34 | Citations (PDF) |
| 316 | Water diffusion is elevated in widespread regions of normal-appearing white matter in multiple sclerosis and correlates with diffusion in focal lesions | 3.9 | 37 | Citations (PDF) |
| 317 | Fatigue is not associated with raised inflammatory markers in multiple sclerosis | 1.0 | 101 | Citations (PDF) |
| 318 | Does adding MS-specific items to a generic measure (the SF-36) improve measurement? | 1.0 | 68 | Citations (PDF) |
| 319 | The SF-36 in multiple sclerosis: why basic assumptions must be tested | 6.3 | 124 | Citations (PDF) |
| 320 | The five item Barthel index | 6.3 | 99 | Citations (PDF) |
| 321 | A new test of memory for multiple sclerosis 1: Format development and stimuli design | 3.9 | 5 | Citations (PDF) |
| 322 | Evidence-based measurement | 1.0 | 233 | Citations (PDF) |
| 323 | Managing Spasticity in People With Multiple Sclerosis: A Goal-Oriented Approach to Intrathecal Baclofen Therapy | 1.5 | 18 | Citations (PDF) |
| 324 | Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial | 6.1 | 164 | Citations (PDF) |
| 325 | Treatment of focal spasticity with botulinum toxin: effect on the ‘positive support reaction’ | 1.5 | 6 | Citations (PDF) |
| 326 | A 1H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis | 1.8 | 72 | Citations (PDF) |
| 327 | A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis | 3.4 | 102 | Citations (PDF) |
| 328 | A retrospective analysis of outcome in severe Guillain-Barre syndrome following combined neurological and rehabilitation management | 2.5 | 27 | Citations (PDF) |
| 329 | Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI | 1.0 | 4 | Citations (PDF) |
| 330 | Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis | 6.3 | 107 | Citations (PDF) |
| 331 | Progressive cerebral atrophy in MS | 1.0 | 208 | Citations (PDF) |
| 332 | Physical rehabilitation has a positive effect on disability in multiple sclerosis patients | 1.0 | 7 | Citations (PDF) |
| 333 | Kurtzke scales revisited: the application of psychometric methods to clinical intuitionBrain, 2000, 123, 1027-1040 | 8.4 | 284 | Citations (PDF) |
| 334 | Evaluating the role of botulinum toxin in the management of focal hypertonia in adults | 6.3 | 107 | Citations (PDF) |
| 335 | No association between the APOE epsilon 4 allele and outcome and susceptibility in primary progressive multiple sclerosis | 6.3 | 37 | Citations (PDF) |
| 336 | The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: A serial diffusion MRI studyBrain, 2000, 123, 1667-1676 | 8.4 | 302 | Citations (PDF) |
| 337 | MTR and T1 provide complementary information in MS NAWM, but not in lesions | 3.9 | 23 | Citations (PDF) |
| 338 | Neurological rehabilitation: from mechanisms to management | 6.3 | 14 | Citations (PDF) |
| 339 | Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations | 6.3 | 115 | Citations (PDF) |
| 340 | A questionnaire assessment of unmet needs for rehabilitation services and resources for people with multiple sclerosis: results of a pilot survey in five European countries | 3.1 | 58 | Citations (PDF) |
| 341 | Community services in multiple sclerosis: still a matter of chance | 6.3 | 77 | Citations (PDF) |
| 342 | Variations in T1 and T2 relaxation times of normal appearing white matter and lesions in multiple sclerosis | 2.1 | 121 | Citations (PDF) |
| 343 | Correlates of Executive Function in Multiple Sclerosis: | 2.3 | 101 | Citations (PDF) |
| 344 | Inpatient rehabilitation in multiple sclerosis | 1.0 | 151 | Citations (PDF) |
| 345 | Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? | 6.3 | 53 | Citations (PDF) |
| 346 | Multisequence MRI in clinically isolated syndromes and the early development of MS | 1.0 | 116 | Citations (PDF) |
| 347 | Measuring handicap in multiple sclerosis | 3.9 | 9 | Citations (PDF) |
| 348 | Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel Index and the Functional Independence Measure | 6.3 | 323 | Citations (PDF) |
| 349 | Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis | 3.9 | 51 | Citations (PDF) |
| 350 | Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome | 3.9 | 118 | Citations (PDF) |
| 351 | Reproducibility of magnetic resonance imaging measurements of spinal cord atrophy: the role of quality assurance | 1.8 | 17 | Citations (PDF) |
| 352 | Evaluating the role of botulinum toxin type A in adults with focal spasticity | 3.5 | 3 | Citations (PDF) |
| 353 | Title is missing! | 1.4 | 5 | Citations (PDF) |
| 354 | Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis | 3.4 | 16 | Citations (PDF) |
| 355 | Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study | 3.4 | 43 | Citations (PDF) |
| 356 | 1 H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis | 3.4 | 131 | Citations (PDF) |
| 357 | Botulinum Toxin | 1.6 | 14 | Citations (PDF) |
| 358 | Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis | 6.1 | 135 | Citations (PDF) |
| 359 | A Direct Demonstration of both Structure and Function in the Visual System: Combining Diffusion Tensor Imaging with Functional Magnetic Resonance Imaging | 4.4 | 86 | Citations (PDF) |
| 360 | Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis | 3.7 | 7 | Citations (PDF) |
| 361 | Management of spasticity in hereditary spastic paraplegia | 1.5 | 4 | Citations (PDF) |
| 362 | Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination | 1.0 | 120 | Citations (PDF) |
| 363 | Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis | 1.0 | 582 | Citations (PDF) |
| 364 | Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination | 1.0 | 0 | Citations (PDF) |
| 365 | Multiple sclerosis: assessment of disability and disability scales | 3.4 | 81 | Citations (PDF) |
| 366 | Improved imaging of the spinal cord in multiple sclerosis using three-dimensional fast spin echo | 2.1 | 18 | Citations (PDF) |
| 367 | Spinal cord atrophy and disability in MS | 1.0 | 224 | Citations (PDF) |
| 368 | Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups | 6.3 | 43 | Citations (PDF) |
| 369 | The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule | 6.3 | 113 | Citations (PDF) |
| 370 | Integrated care pathways in multiple sclerosis rehabilitation: completing the audit cycle | 3.9 | 29 | Citations (PDF) |
| 371 | Multiple Sclerosis: Rehabilitation Measures | 1.7 | 17 | Citations (PDF) |
| 372 | The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-upBrain, 1998, 121, 495-503 | 8.4 | 441 | Citations (PDF) |
| 373 | Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination | 6.3 | 98 | Citations (PDF) |
| 374 | Identification of brain atrophy with MRI in MS | 3.9 | 4 | Citations (PDF) |
| 375 | MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences | 6.3 | 51 | Citations (PDF) |
| 376 | An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosisBrain, 1998, 121, 967-975 | 8.4 | 87 | Citations (PDF) |
| 377 | Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical featuresBrain, 1998, 121, 225-231 | 8.4 | 44 | Citations (PDF) |
| 378 | Central motor conduction time in progressive multiple sclerosis. Correlations with MRI and disease activityBrain, 1998, 121, 1109-1116 | 8.4 | 47 | Citations (PDF) |
| 379 | Symptomatic treatment in multiple sclerosis | 3.8 | 33 | Citations (PDF) |
| 380 | Longitudinal study of soluble adhesion molecules in multiple sclerosis | 1.0 | 88 | Citations (PDF) |
| 381 | The effect of botulinum toxin on hand function after incomplete spinal cord injury at the level of C5/6: a case report | 3.1 | 37 | Citations (PDF) |
| 382 | Prospective study of neurorehabilitation in multiple sclerosis. | 6.3 | 22 | Citations (PDF) |
| 383 | Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. | 6.3 | 90 | Citations (PDF) |
| 384 | Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load | 6.3 | 28 | Citations (PDF) |
| 385 | Multiple sclerosis lesion detection in the brain: A comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo | 1.0 | 116 | Citations (PDF) |
| 386 | An electrophysiological study of the mechanism of fatigue in multiple sclerosisBrain, 1997, 120, 299-315 | 8.4 | 232 | Citations (PDF) |
| 387 | Executive function in multiple sclerosis. The role of frontal lobe pathology | 8.4 | 267 | Citations (PDF) |
| 388 | 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis | 6.3 | 208 | Citations (PDF) |
| 389 | Effects of anti‐CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production | 1.0 | 39 | Citations (PDF) |
| 390 | Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis | 8.4 | 72 | Citations (PDF) |
| 391 | Integrated care pathways: evaluating inpatient rehabilitation in stroke | 0.2 | 8 | Citations (PDF) |
| 392 | Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imagingBrain, 1997, 120, 1149-1161 | 8.4 | 159 | Citations (PDF) |
| 393 | Primary progressive multiple sclerosisBrain, 1997, 120, 1085-1096 | 8.4 | 385 | Citations (PDF) |
| 394 | Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials | 3.4 | 71 | Citations (PDF) |
| 395 | Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast flair and fast spin echo | 3.4 | 70 | Citations (PDF) |
| 396 | The transverse magnetisation decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis | 3.4 | 33 | Citations (PDF) |
| 397 | Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis | 3.4 | 56 | Citations (PDF) |
| 398 | Magnetisation transfer ratio measurement in the cervical spinal cord: a preliminary study in multiple sclerosis | 2.1 | 45 | Citations (PDF) |
| 399 | The impact of inpatient rehabilitation on progressive multiple sclerosis | 6.6 | 231 | Citations (PDF) |
| 400 | Progressive cerebral atrophy in multiple sclerosis A serial MRI studyBrain, 1996, 119, 2009-2019 | 8.4 | 477 | Citations (PDF) |
| 401 | Health-Related Quality of Life in People with Multiple Sclerosis Undergoing Inpatient Rehabilitation | 3.4 | 16 | Citations (PDF) |
| 402 | New treatments for multiple sclerosis | 3.8 | 12 | Citations (PDF) |
| 403 | Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon lossBrain, 1996, 119, 1415-1415 | 8.4 | 1 | Citations (PDF) |
| 404 | Rehabilitation in a neuroscience centre: the role of expert assessment and selection | 0.2 | 16 | Citations (PDF) |
| 405 | Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters | 3.4 | 51 | Citations (PDF) |
| 406 | Rehabilitation of incomplete spinal cord pathology: Factors affecting prognosis and outcome | 3.4 | 16 | Citations (PDF) |
| 407 | Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups | 3.4 | 38 | Citations (PDF) |
| 408 | Multiple sclerosis: Symptomatic treatment | 3.4 | 51 | Citations (PDF) |
| 409 | A little bit of toxin does you good? | 1.5 | 3 | Citations (PDF) |
| 410 | Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. | 6.3 | 351 | Citations (PDF) |
| 411 | A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. | 6.3 | 74 | Citations (PDF) |
| 412 | MRI dynamics of brain and spinal cord in progressive multiple sclerosis. | 6.3 | 178 | Citations (PDF) |
| 413 | Evaluating neurological outcome measures: the bare essentials. | 6.3 | 133 | Citations (PDF) |
| 414 | Spinal cord atrophy and disability in multiple sclerosisBrain, 1996, 119, 701-708 | 8.4 | 640 | Citations (PDF) |
| 415 | Outcomes-based research in neurorehabilitation: The need for multidisciplinary team involvement | 2.5 | 10 | Citations (PDF) |
| 416 | A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis | 3.9 | 28 | Citations (PDF) |
| 417 | Resolution of Left Hemisphere Cognitive Dysfunction in Multiple Sclerosis with Magnetic Resonance Correlates: A Case Report | 1.4 | 14 | Citations (PDF) |
| 418 | Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis | 1.0 | 195 | Citations (PDF) |
| 419 | Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. | 6.3 | 63 | Citations (PDF) |
| 420 | Guidelines for physicians with patients on IFN beta-1b | 1.0 | 48 | Citations (PDF) |
| 421 | Spinal MRI in patients with suspected multiple sclerosis and negative brain MRIBrain, 1996, 119, 709-714 | 8.4 | 162 | Citations (PDF) |
| 422 | Correspondence | 2.5 | 0 | Citations (PDF) |
| 423 | The assessment of handicap: An evaluation of the Environmental Status Scale | 2.5 | 23 | Citations (PDF) |
| 424 | Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting | 2.5 | 30 | Citations (PDF) |
| 425 | Correlations between changes in disability and T
2
‐weighted brain MRI activity in multiple sclerosis | 1.0 | 299 | Citations (PDF) |
| 426 | Disambiguating verbal comments in social interaction: A computer model of meaning* | 2.2 | 3 | Citations (PDF) |
| 427 | Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. | 6.3 | 38 | Citations (PDF) |
| 428 | Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon lossBrain, 1995, 118, 1583-1592 | 8.4 | 402 | Citations (PDF) |
| 429 | The Functional Independence Measure: A comparative validity and reliability study | 2.5 | 466 | Citations (PDF) |
| 430 | Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosisBrain, 1995, 118, 1601-1612 | 8.4 | 185 | Citations (PDF) |
| 431 | Serial MRI of the brain in asymptomatic patients infected with HIV: results from the UCMSM/Medical Research Council neurology cohort. | 6.3 | 30 | Citations (PDF) |
| 432 | Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. | 6.3 | 35 | Citations (PDF) |
| 433 | Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study | 3.4 | 48 | Citations (PDF) |
| 434 | Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-? | 6.6 | 70 | Citations (PDF) |
| 435 | Correlation of magnetization transfer ration with clinical disability in multiple sclerosis | 6.6 | 345 | Citations (PDF) |
| 436 | Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs | 2.1 | 98 | Citations (PDF) |
| 437 | A comparison of the pathology of primary and secondary progressive multiple sclerosisBrain, 1994, 117, 759-765 | 8.4 | 290 | Citations (PDF) |
| 438 | Increased expression of high affinity IL-2 receptors and β-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosisBrain, 1994, 117, 307-315 | 8.4 | 62 | Citations (PDF) |
| 439 | Database for serial magnetic resonance imaging in multiple sclerosis | 2.1 | 5 | Citations (PDF) |
| 440 | Degos disease and spastic paraplegia | 1.1 | 10 | Citations (PDF) |
| 441 | Brain MRI changes in phenylketonuria: Associations with dietary statusBrain, 1993, 116, 811-821 | 8.4 | 164 | Citations (PDF) |
| 442 | A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosisBrain, 1993, 116, 569-602 | 8.4 | 74 | Citations (PDF) |
| 443 | Seizures due to multiple sclerosis: seven patients with MRI correlations. | 6.3 | 80 | Citations (PDF) |
| 444 | Spinal cord MRI using multi‐array coils and fast spin echo | 1.0 | 351 | Citations (PDF) |
| 445 | Spinal cord MRI using multi‐array coils and fast spin echo | 1.0 | 78 | Citations (PDF) |
| 446 | Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration | 1.0 | 243 | Citations (PDF) |
| 447 | MATTERS ARISING: Miller et al reply: | 6.3 | 0 | Citations (PDF) |
| 448 | High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. | 6.3 | 172 | Citations (PDF) |
| 449 | EDMUS, a European database for multiple sclerosis. | 6.3 | 289 | Citations (PDF) |
| 450 | β‐Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: A regulatory role for cortisol and interleukin‐1 | 6.6 | 73 | Citations (PDF) |
| 451 | Acute exercise: Buffering psychosocial stress responses in women. | 1.6 | 35 | Citations (PDF) |
| 452 | Multiple sclerosis and HLA: Is the susceptibility gene really HLA-DR or -DQ? | 1.0 | 63 | Citations (PDF) |
| 453 | Major differences in the dynamics of primary and secondary progressive multiple sclerosis | 6.6 | 502 | Citations (PDF) |
| 454 | Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. | 6.3 | 355 | Citations (PDF) |
| 455 | Biochemical changes within a multiple sclerosis plaque in vivo. | 6.3 | 24 | Citations (PDF) |
| 456 | Destructive lesions in demyelinating disease. | 6.3 | 55 | Citations (PDF) |
| 457 | Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. | 0.1 | 251 | Citations (PDF) |
| 458 | Heterogeneity of blood‐brain barrier changes in multiple sclerosis | 1.0 | 205 | Citations (PDF) |
| 459 | Patterns of disease activity in multiple sclerosis. | 0.1 | 13 | Citations (PDF) |
| 460 | MRI of thoracic cord in tropical spastic paraparesis. | 6.3 | 12 | Citations (PDF) |
| 461 | LETTERS TO THE EDITOR: MRI of thoracic cord in tropical spastic paraparesis | 6.3 | 2 | Citations (PDF) |
| 462 | BREAKDOWN OF THE BLOOD-BRAIN BARRIER PRECEDES SYMPTOMS AND OTHER MRI SIGNS OF NEW LESIONS IN MULTIPLE SCLEROSISBrain, 1990, 113, 1477-1489 | 8.4 | 574 | Citations (PDF) |
| 463 | Neurological deterioration in young adults with phenylketonuria | 62.1 | 205 | Citations (PDF) |
| 464 | An improved radioimmunoassay for myelin basic protein-like immunoreactive material in cerebrospinal fluid | 3.5 | 9 | Citations (PDF) |
| 465 | Two distinct deficits of visual tracking caused by unilateral lesions of cerebral cortex in humans | 6.6 | 141 | Citations (PDF) |
| 466 | Patterns of selective involvement of thigh muscles in neuromuscular disease | 2.2 | 32 | Citations (PDF) |
| 467 | Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. | 6.3 | 157 | Citations (PDF) |
| 468 | Bell's palsy and HIV infection. | 6.3 | 43 | Citations (PDF) |
| 469 | A Clinical and Laboratory Study of Benign Multiple Sclerosis | 0.5 | 25 | Citations (PDF) |
| 470 | Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course. | 6.3 | 15 | Citations (PDF) |
| 471 | Painful Extremities and Neurological Disorder in Essential Thrombocythaemia | 1.8 | 9 | Citations (PDF) |
| 472 | Pulmonary actinomycosis in children | 1.8 | 24 | Citations (PDF) |
| 473 | Influence of Social Desirability upon the Group Personality Projective Test | 2.1 | 0 | Citations (PDF) |
| 474 | SYMPTOMATIC MANAGEMENT AND REHABILITATION IN MULTIPLE SCLEROSIS | 6.3 | 19 | Citations (PDF) |
| 475 | Title is missing! 0 | | 1 | Citations (PDF) |
| 476 | Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis | 3.7 | 2 | Citations (PDF) |
| 477 | Neuronal plasticity during motor rehabilitation training after spinal cord injury | 4.4 | 1 | Citations (PDF) |
| 478 | Thirty-Year Trends in Multiple Sclerosis Prevalence, Lifestyle Factors, and Mortality in England | 17.6 | 0 | Citations (PDF) |
| 479 | Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis – Authors’ reply | 17.9 | 0 | Citations (PDF) |
